{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:45:58Z","timestamp":1793234758487,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jdermsci.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:14:59Z","timestamp":1625570099000},"page":"135-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton\u2019s tyrosine kinase inhibitor, in pemphigus"],"prefix":"10.1016","volume":"103","author":[{"given":"Jun","family":"Yamagami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiharu","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ichijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Amagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2021.07.002_bib0005","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jdermsci.2021.07.002_bib0010","series-title":"Dermatology","first-page":"494","article-title":"Pemphigus","author":"Amagai","year":"2017"},{"key":"10.1016\/j.jdermsci.2021.07.002_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2021.07.002_bib0020","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front. Immunol."},{"issue":"10201","key":"10.1016\/j.jdermsci.2021.07.002_bib0025","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jdermsci.2021.07.002_bib0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/1346-8138.12486","article-title":"Japanese guidelines for the management of pemphigus","volume":"41","author":"Committee for Guidelines for the Management of Pemphigus Disease","year":"2014","journal-title":"J. Dermatol."},{"issue":"10","key":"10.1016\/j.jdermsci.2021.07.002_bib0035","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/1744666X.2020.1672535","article-title":"Treatment of pemphigus vulgaris: part 1 - current therapies","volume":"15","author":"Yanovsky","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jdermsci.2021.07.002_bib0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jdermsci.2021.07.002_bib0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0609.2009.01215.x","article-title":"Rapid infusion of rituximab over 60 min","volume":"82","author":"Tuthill","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jdermsci.2021.07.002_bib0050","article-title":"Rapid infusion rituximab for maintenance therapy: is it feasible?","volume":"2013","author":"Patel","year":"2013","journal-title":"Leuk. Res. Treatment"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.07.002_bib0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Biol."},{"issue":"2\u20133","key":"10.1016\/j.jdermsci.2021.07.002_bib0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/IR:23:2-3:147","article-title":"Regulation of B lymphocyte development and activation by Bruton\u2019s tyrosine kinase","volume":"23","author":"Khan","year":"2001","journal-title":"Immunol. Res."},{"issue":"12","key":"10.1016\/j.jdermsci.2021.07.002_bib0065","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2021.07.002_bib0070","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1038\/s41598-017-14089-2","article-title":"Peripheral CD19(hi) B cells exhibit activated phenotype and functionality in promoting IgG and IgM production in human autoimmune diseases","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"issue":"5;Suppl1","key":"10.1016\/j.jdermsci.2021.07.002_bib0075","article-title":"A new treatment for autoimmune blistering diseases - the efficacy of the Bruton\u2019s tyrosine kinase inhibitor PRN473 in canine pemphigus foliaceus","volume":"74","author":"Outerbridge","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2021.07.002_bib0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2020","journal-title":"Neuro. Oncol."},{"issue":"9","key":"10.1016\/j.jdermsci.2021.07.002_bib0085","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/cas.14561","article-title":"A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"111","author":"Sekiguchi","year":"2020","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.jdermsci.2021.07.002_bib0090","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/cas.13983","article-title":"Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan","volume":"110","author":"Munakata","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jdermsci.2021.07.002_bib0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.36648\/2248-9215.9.1.79","article-title":"Bruton\u2019s tyrosine kinase (Btk) inhibitor tirabrutinib prevents the development of murine lupus","volume":"9","author":"Ariza","year":"2019","journal-title":"Eur. J. Exp. Biol."},{"issue":"10","key":"10.1016\/j.jdermsci.2021.07.002_bib0100","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.jdermsci.2021.07.002_bib0105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm. Venereol."},{"issue":"6","key":"10.1016\/j.jdermsci.2021.07.002_bib0110","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.jdermsci.2021.07.002_bib0115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/1346-8138.14732","article-title":"Rituximab therapy for refractory autoimmune bullous diseases: a multicenter, open-label, single-arm, phase 1\/2 study on 10 Japanese patients","volume":"46","author":"Kurihara","year":"2019","journal-title":"J. Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.07.002_bib0120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjd.13350","article-title":"A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone","volume":"172","author":"Hall","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2021.07.002_bib0125","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/jdv.16188","article-title":"Results of the guideline-based treatment for pemphigus: a single-centre experience with 84 cases","volume":"34","author":"Kakuta","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"10.1016\/j.jdermsci.2021.07.002_bib0130","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2021.07.002_bib0135","doi-asserted-by":"crossref","first-page":"23002","DOI":"10.1038\/srep23002","article-title":"Effects of systemically administered hydrocortisone on the human immunome","volume":"6","author":"Olnes","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jdermsci.2021.07.002_bib0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121001481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121001481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:51:26Z","timestamp":1760331086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181121001481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0923181121001481"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.07.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton\u2019s tyrosine kinase inhibitor, in pemphigus","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}